What is CRDF's current stock price?

CRDF (Cardiff Oncology, Inc.) is currently trading at $1.78 with a market cap of $121.7M.

What sector is Cardiff Oncology, Inc. in?

Cardiff Oncology, Inc. (CRDF) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

CRDF Cardiff Oncology, Inc.

Healthcare

$1.78-0.56%ClosedMarket Cap: $121.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.51

P/S

231.81

EV/EBITDA

-2.49

DCF Value

$0.02

FCF Yield

-30.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

-2147.8%

Operating Margin

-9033.9%

Net Margin

-8527.2%

ROE

-95.5%

ROA

-91.0%

ROIC

-134.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$41.0K	$-12.4M	$—
Q4 null	$243.0K	$-7.2M	$—
FY null	$593.0K	$-45.9M	$—
Q3 null	$120.0K	$-11.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell

Piper SandlerOverweight

2026-02-25

HC Wainwright & Co.Buy

2026-01-28

HC Wainwright & Co.Buy

2025-08-06

Trading Activity

Insider Trades

View All

Aggarwal Ajayofficer: Chief Operating Officer

SellTue Apr 28

Aggarwal Ajay

SellTue Apr 28

Smeal Todofficer: Chief Scientific Officer

SellThu Apr 16

Muntner Joshua Bofficer: Chief Financial Officer

SellThu Apr 16

Muntner Joshua Bofficer: Chief Financial Officer

SellThu Apr 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.36

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Peers